CELL EVALUATION & THERAPY
CELL EVALUATION & THERAPY
批准号:
8695829
负责人:
Andrew S Kraft
金额:
$6.47万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2019-03-31
关键词:
ApoptosisBiological AssayCancer CenterCancer Center Support GrantCell CycleCell ProliferationCell SeparationCell TherapyCell surfaceCellsClinicalClinical ResearchConsultationsCyclic GMPDataData AnalysesDetectionDevelopmentDoctor of PhilosophyEquipmentExperimental DesignsFlow CytometryFundingGoalsHealthcareHumanImmune responseImmunologic MonitoringImmunophenotypingInstructionLaboratoriesLasersMalignant NeoplasmsMeasurementMedicalMembrane ProteinsMethodologyMethodsMissionPatientsPeer ReviewPhasePopulationPreparationPublicationsRegulationResearchResearch PersonnelResearch Project GrantsResource SharingSamplingServicesSideSouth CarolinaSpeedStaining methodStainsTechnologyTherapeuticTherapy EvaluationTissuesTrainingTranslational ResearchUniversitiesbasecell preparationcost effectivegene therapyinnovationmanufacturing facilitymembernovelpre-clinicalresearch studysuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Hollings Cancer Center (HCC) Cell Evaluation & Therapy (CET) Shared Resource offers HCC
investigators comprehensive analytic flow cytometry and high-speed cell sorting services and the capacity to
generate human cellular and tissue-based products for use in translational research. The mission of the
CET Shared Resource is to provide an integrated platform where HCC users can evaluate pre-clinical or
clinical experimental data in a cell-specific manner and use the cell-manufacturing facility to bring the cellular
product to patients. Directed by Kevin F. Staveley-O'Carroll, MD, PhD, with two Associate Directors,
Amanda C. LaRue, PhD and Shikhar Mehrotra, PhD, this facility provides extensive expertise, an active
educational platform, and development of new methodologies within the facility.
The specific objectives of the HCC CET Shared Resource are to provide:
• Multi-parametric and multi-laser measurements including apoptosis, cell proliferation, cell cycle
distribution, and immunophenotyping, as well as detection of intracellular proteins, membrane
perturbations, and bioactive molecules.
• Expanded cell therapy and gene therapy-based bio-therapeutic products for Phase I and II clinical
studies employing current cGMP as required by federal regulations.
• Immune monitoring services to evaluate the immune response in patients and provide data for basic
laboratory experiments.
• Regulatory expertise in the preparation of cell and possibly gene therapy based INDs.
• High-speed cell sorting based on cell surface marker immunostaining and/or side-population staining.
• Consultation and assistance concerning experimental design, sample preparation, and data analysis.
• Training in the use of routine flow cytometric technology and analytical equipment.
• Advanced training in novel flow cytometric assays that are new and/or specific to HCC researchers'
applications.
• New methods to assist HCC members in performing cutting-edge research.
CET-supported experiments during the current CCSG project period have led to the success of more than 18
NCI-funded research project grants and more than 100 peer-reviewed publications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of RNA Decapping and Degradation: A novel approach to prostate cancer therapy
-
批准号:10758110
-
项目类别:
-
资助金额:$39.72万
-
财政年份:2023
-
负责人:Andrew S Kraft
-
依托单位:
Pim 1 Protein Kinase in Regulating Stromal Cell Biology in Prostate Cancer
-
批准号:8855025
-
项目类别:
-
资助金额:$19.96万
-
财政年份:2015
-
负责人:Andrew S Kraft
-
依托单位:
MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan
-
批准号:8486908
-
项目类别:
-
资助金额:$16.38万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:8577635
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:9039263
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:8735893
-
项目类别:
-
资助金额:$7.23万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:9320825
-
项目类别:
-
资助金额:$31.85万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:8891388
-
项目类别:
-
资助金额:$31.11万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Senior Leadership
-
批准号:8533978
-
项目类别:
-
资助金额:$6.58万
-
财政年份:2012
-
负责人:Andrew S Kraft
-
依托单位:
LIPIDOMICS SHARED RESOURCE GROUP
-
批准号:8695810
-
项目类别:
-
资助金额:$8.14万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
BIOSTATISTICS SHARED RESOURCE GROUP
-
批准号:8695824
-
项目类别:
-
资助金额:$12.18万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
CELL AND MOLECULAR IMAGING
-
批准号:8695817
-
项目类别:
-
资助金额:$7.26万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:8923675
-
项目类别:
-
资助金额:$14.74万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:8322869
-
项目类别:
-
资助金额:$5.76万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Novel Inhibitors of Pim Protein Kinases
-
批准号:7743696
-
项目类别:
-
资助金额:$25.79万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:7795202
-
项目类别:
-
资助金额:$155.75万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
BIOREPOSITORY & TISSUE ANALYSIS
-
批准号:8695842
-
项目类别:
-
资助金额:$6.65万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:7931536
-
项目类别:
-
资助金额:$254.87万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
CANCER CONTROL
-
批准号:8695807
-
项目类别:
-
资助金额:$3.08万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:8072105
-
项目类别:
-
资助金额:$140.13万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
海外基金